ACE2 and COVID-19: The current paper presents a study, using the same cohort of patients [22], investigating whether DNA methylation levels of the ACE2 promoter are associated with the development of long-lasting post-COVID-19 pain in individuals who had been hospitalized due to SARS-CoV-2 infection.